Insilico Medicine reposted this
Exciting news from yesterday’s press webinar by Insilico Medicine! The company introduced two state of the art generative models, DORA and Precious-3 GPT 🚀 The first one is DORA is a state-of-the-art AI assistant designed to transform the drafting of medical research papers, case studies, and grant applications. DORA harnesses the power of multiple AI and large language models (LLMs) to assist researchers, particularly early-career professionals and non-native English speakers. Unlike traditional generative AI, DORA doesn’t provide instant outputs. Instead, it integrates reinforcement learning and hundreds of interconnected agents, ensuring a thorough, multi-step referencing process. This aims for high accuracy and contextual relevance, though Insilico Medicine notes that human proofreading is still essential for the final draft. Why DORA? The goal is to democratize research support. By providing a sophisticated digital assistant, DORA enables medical professionals with limited research time or institutional backing to effectively formulate and annotate hypotheses, turning their insights into publications and blog posts. 🚀 The second tool, Precious-3 GPT, is an open-source gen AI model for aging research. Precious-3 GPT is a multimodal system targeting aging and related diseases, which ingests clinical data, including compound structures, DNA, and omics-based test results, as well as text-based reports and published research. It then predicts drug sensitivity and cellular interactions while considering the molecular aspects of aging. Why Precious-3 GPT? The aim is to uncover relationships between preclinical models and humans, facilitating advanced research on aging and diseases like osteoarthritis. Researchers can query targets implicated in aging across different species, fostering a deeper understanding and innovative approaches in biomedical research. Try the new open source tools on Discord or Hugging Face (links in the comments) Ever since I backed Insilico Medicine in 2016, It’s never been a lack of innovation coming from the company on a regular basis! Not only did they become a leading AI in drug discovery company with a robust clinical pipeline, but the team is also constantly introducing novel tools for the research community. I really like startup teams with a strong culture of innovation, but also focused on achieving practical results. That’s the type of companies I am ready to support as a business angel or via our VC funds: LongeVC for the longevity and biotech sector, and AniVC for the pets industry, respectively. Reach out if you have bold ideas and you are ready to execute on those ideas! Kudos Alex Zhavoronkov Alex Aliper and Insilico team!💫 #genAI #generativeAI #biotech #entrepreneurship Image credit: Insilico Medicine
Alex Zhavoronkov
1mo
Thank you! Please use DORA - we are planning tools for investor DD as well
Claire Holden
1mo
Sounds like a useful tool but is it too late to change the name? DORA already means 'Declaration on Research Assessment' which is a known set of guidelines used in research publications and grant proposals
Longevity and biotech VC
1moNews source: https://www.biopharmatrend.com/post/873-insilico-medicine-unveils-ai-assistant-for-medical-research-drafting/ Try open source model Precious3GPT: https://insilico.com/repository/precious3gpt Precious Series: https://insilico.com/precious